Therapeutic use of anti-CS1 antibodies
AssigneeAbbVie Biotherapeutics Inc.
InventorsMarna Williams, J. Yun Tso, Nicholas F. Landolfi, Gao Liu
Life of this patent
Estimating the term…
Abstract
The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
Claims36
A method of treating myeloma, comprising administering to a patient suffering from myeloma but who has not developed clinical manifestations of myeloma, a therapeutically effective amount of a monoclonal anti-CS1 antibody or an anti-CS1 antigen binding fragment, wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment binds to a protein encoded by SEQ ID NO:1.
A method of treating myeloma, comprising administering to a patient suffering from myeloma but who has not developed clinical manifestations of myeloma, a therapeutically effective amount of a conjugate compound comprising a monoclonal anti-CS1 antibody or an anti-CS1 antigen binding fragment linked to an effector moiety, wherein the monoclonal anti-CS1 antibody or anti-CS1 antigen binding fragment binds to a protein encoded by SEQ ID NO:1.
Dependencies are inferred from the claim text.